Leukemias


Share

Program Content

Activities

  • ASH 2024 Leukemias
    CCO’s Conference to Clinic Highlights From the ASH 2024 Annual Meeting: Leukemias
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 15, 2025

    Expires: July 14, 2025

Activities

RATIFY 10-Yr Follow-Up
CALGB 10603/RATIFY: 10-Yr Follow-up of Midostaurin vs Placebo Combined With Intensive CT for Newly Diagnosed FLT3-Mutant AML 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2024

Expires: December 09, 2025

ASC4FIRST Asciminib
ASC4FIRST: Phase III Trial of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor as First-line Therapy for Chronic Myeloid Leukemia in Chronic Phase
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2024

Expires: December 10, 2025

ASCEND CML
ASCEND-CML: Update From Phase II Trial of Frontline Asciminib in Patients With CP-CML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

CLAD LDAC VEN in ND AML
Phase II Trial of Cladribine + LDAC + Venetoclax Alternating With Azacitidine + Venetoclax in Patients With Newly Diagnosed AML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

GIMEMA ALL2820
GIMEMA ALL2820: Intermediate Analysis of Phase III Trial of First-line Ponatinib + Blinatumomab in Adults With Ph+ Acute Lymphoblastic Leukemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

Revumenib in Acute Leukemias
AUGMENT-101 and SAVE: Revumenib-Based Therapy in R/R Acute Leukemias
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2024

Expires: December 15, 2025

Faculty

cover img faculity

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation